Predict your next investment

Venture Capital
decheng.com

See what CB Insights has to offer

Investments

82

Portfolio Exits

17

Funds

6

Service Providers

1

About Decheng Capital

Decheng Capital is an investment firm that provides capital and strategic support to early-stage life science companies with innovative technologies and growth-stage healthcare companies.

Decheng Capital Headquarter Location

3000 Sand Hill Road Building 2, Suite 110

Menlo Park, California, 94025,

United States

650-233-0688

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Decheng Capital News

Watchmaker Genomics raises $40M in Series A

Jun 13, 2022

BOULDER — As the life sciences industry in the area continues to bloom, Watchmaker Genomics Inc., one of the newer companies in the region has completed a Series A funding round as it prepares to ramp up its research and development capabilities and expand its workforce. Watchmaker Genomics closed its $40 million Series A this month, bringing its fundraising total to $53.5 million since its founding in 2019. The round was led by Decheng Capital with co-investment from Eclipse Ventures. Watchmaker develops reagents that are used in genetic testing, primarily for cancer tumor profiling. They are also used in testing inherited and infectious diseases. The company launched its first product in 2020 and has since become profitable, with 175% year-over-year revenue growth. Watchmaker CEO Trey Foskett told BizWest that the company’s founders had various backgrounds in genetic engineering, manufacturing, computational biology and more. They all participated in early research of the tools and technologies that Watchmaker now uses, and they shared a vision for how those could be practically used. “Now we see that research translate into true clinical applications,” Foskett said. “These markets have gotten very large over the past 10 to 15 years. The diversity of applications has just blossomed.” Foskett said Watchmaker will use the capital it raised in the Series A to expand its commercial channels and manufacturing capacity while developing new products for clinical sequencing applications, such as single-cell analysis, epigenetics and cell-free DNA. The company will also accelerate its workforce growth, Foskett said. Watchmaker started with three employees. It now has about 90, with plans to expand to 150 by the end of the year. Foskett said Watchmaker is thrilled to be at the heart of the explosion of the Boulder life sciences industry. Watchmaker is located in Flatiron Park, the life sciences campus that sold for $625 million in April, the richest real estate transaction in Colorado history. The buyer, BioMed Realty LLC, is the largest private life sciences real estate company in the county. “It’s a nice tie-in with the investment we’re making in ourselves,” Foskett said. “Nationally, from a life sciences perspective, there’s a lot of capital coming into the Front Range. We’re right in the bullseye for that thesis. We want to see a critical mass of life sciences companies here.” BOULDER — As the life sciences industry in the area continues to bloom, Watchmaker Genomics Inc., one of the newer companies in the region has completed a Series A funding round as it prepares to ramp up its research and development capabilities and expand its workforce. Watchmaker Genomics closed its $40 million Series A this month, bringing its fundraising total to $53.5 million since its founding in 2019. The round was led by Decheng Capital with co-investment from Eclipse Ventures. Watchmaker develops reagents that are used in genetic testing, primarily for cancer tumor profiling. They are also used in testing inherited and… This article has been intentionally blurred. You must purchase a subscription to view the rest of this content. Want to See More! ?

Decheng Capital Investments

82 Investments

Decheng Capital has made 82 investments. Their latest investment was in Upstream Bio as part of their Series A on June 6, 2022.

CBI Logo

Decheng Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/2/2022

Series A

Upstream Bio

$200M

Yes

2

6/2/2022

Series A

Watchmaker Genomics

$40M

Yes

5

5/17/2022

Series B

Mirvie

Yes

5

5/12/2022

Private Equity

Subscribe to see more

Subscribe to see more

10

2/18/2022

Series D

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/2/2022

6/2/2022

5/17/2022

5/12/2022

2/18/2022

Round

Series A

Series A

Series B

Private Equity

Series D

Company

Upstream Bio

Watchmaker Genomics

Mirvie

Subscribe to see more

Subscribe to see more

Amount

$200M

$40M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

5

5

10

10

Decheng Capital Portfolio Exits

17 Portfolio Exits

Decheng Capital has 17 portfolio exits. Their latest portfolio exit was Apexigen on March 18, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/18/2022

Acq - Pending

$99M

2

9/24/2021

IPO

$99M

Public

21

7/22/2021

Reverse Merger

$99M

4

7/20/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

5/17/2021

Acq - P2P

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/18/2022

9/24/2021

7/22/2021

7/20/2021

5/17/2021

Exit

Acq - Pending

IPO

Reverse Merger

Acquired

Acq - P2P

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

2

21

4

10

10

Decheng Capital Fund History

6 Fund Histories

Decheng Capital has 6 funds, including Decheng Capital China Life Sciences USD Fund II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/31/2015

Decheng Capital China Life Sciences USD Fund II

Multi-Stage Venture Capital

Closed

2

6/6/2013

Decheng Capital China Life Sciences USD Fund I LP

Subscribe to see more

Subscribe to see more

$99M

10

Decheng Investment Fund

Subscribe to see more

Subscribe to see more

10

Decheng Capital Global Life Sciences Fund IV

10

Decheng Capital China Life Sciences USD Fund III

Subscribe to see more

Subscribe to see more

10

Closing Date

12/31/2015

6/6/2013

Fund

Decheng Capital China Life Sciences USD Fund II

Decheng Capital China Life Sciences USD Fund I LP

Decheng Investment Fund

Decheng Capital Global Life Sciences Fund IV

Decheng Capital China Life Sciences USD Fund III

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$99M

Sources

2

10

10

10

10

Decheng Capital Service Providers

1 Service Provider

Decheng Capital has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

Decheng Capital Team

3 Team Members

Decheng Capital has 3 team members, including current Founder, Managing Director, Min Cui.

Name

Work History

Title

Status

Min Cui

Founder, Managing Director

Current

Xiangmin c

Bay City Capital

Managing Director

Current

Min Cui

Managing Director

Current

Name

Min Cui

Xiangmin c

Min Cui

Work History

Bay City Capital

Title

Founder, Managing Director

Managing Director

Managing Director

Status

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.